Pentadecanoic acid (C15:0) has been associated with cardiometabolic benefits that may reduce the risk of cardiovascular disease, according to recent studies.
Does pentadecanoic acid (C15:0) impact cardiovascular disease biology and risk?
This narrative review summarizes the current evidence on the cardiometabolic benefits and role of pentadecanoic acid (C15:0) in cardiovascular disease.
Absolute Event Rate: 0% vs 0%
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide despite major advances in prevention and treatment. The odd-chain saturated fatty acid pentadecanoic acid (C15:0), primarily obtained from dairy fat, has been associated with cardiometabolic benefits. To summarize recent advances in understanding the role of pentadecanoic acid (C15:0) in CVD biology and risk, and to identify knowledge gaps and future research priorities. A narrative review was conducted, drawing on 115 PubMed-indexed studies on odd-chain fatty acids (OCFAs) and cardiovascular outcomes, as well as illustrative mechanistic studies of C15:0. This narrative review synthesized evidence from approximately 115 PubMed-indexed studies on OCFAs and cardiovascular outcomes, along with mechanistic studies of C15:0, identified through targeted searches in PubMed, Scopus, and Web of Science from January 2000 through May 2025.
Joseph Mercola (Wed,) reported a other. Pentadecanoic acid (C15:0) has been associated with cardiometabolic benefits that may reduce the risk of cardiovascular disease, according to recent studies.